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Dermatomyositis (DM) is a unique inflammatory myopathy with clinical findings of proximal muscle weakness, characteristic rash,
and elevated muscle enzymes. The association of DM and malignancy, most commonly adenocarcinoma, is well known. There have
been few case reports of primary myelofibrosis associated with DM. We present the case of a 69-year-old male with a history of
polycythemia vera (PV) who developed proximal muscle weakness, dysphagia, and rash. He was found to have elevated creatinine
kinase and skin biopsy was consistent with DM. Due to persistent pancytopenia a bone marrow biopsy was performed and showed
postpolycythemic myelofibrosis. To our knowledge, this is the first case reported of this unique association.

1. Introduction
Dermatomyositis (DM) is an autoimmune mediated inflammatory myopathy characterized by proximal muscle weakness and classic dermatologic findings including violaceous
pigmentation (heliotrope sign) [1]. Though primarily idiopathic, DM has been associated with underlying malignancies in a paraneoplastic manner [1–4]. To our knowledge, this
is the first case report with DM associated with secondary
myelofibrosis following polycythemia vera.

2. Case Report
A 69-year-old male with a 15-year history of polycythemia
vera (PV), JAK2 V617 positive, presented with a chief complaint of worsening weakness over 4 days. His bilateral upper
and lower extremities became spontaneously weak without
pain, and he reported difficulty ambulating. He also noted
significant dysphagia and mild hoarseness, urinary retention,
and constipation.
The patient’s PV had previously been managed with
hydroxyurea which was discontinued 2 months prior due
to pancytopenia. Patient denied any fevers or night sweats;
however, he did endorse weight loss and fatigue due to poor
oral intake secondary to dysphagia.

On presentation, the patient was vitally stable. Physical
exam was significant only for marked proximal, bilateral,
upper, and lower extremity weakness. Splenomegaly was
absent. Patient was also noted to have a violaceous rash across
his forehead.
Initial complete blood cell count was significant for
leukopenia with left shift (WBC 3.1 g/dL), normocytic anemia
(Hgb 7.0 g/dL, MCV 89.9 fL), and a normal platelet count.
Peripheral blood smear noted teardrop red blood cells and
circulating nucleated red cells (Figure 1). ESR was mildly
elevated (26) as was CRP (8.5) indicative of an inflammatory
state. Labs supportive of myositis included elevated creatinine
kinase (6201 U/L), aldolase (42 U/L), LDH (747 U/L), and
myoglobin (2843 mcg/L).
MRI with contrast of the spine and brachial plexus were
positive for edema of all visualized muscle groups compatible
with myositis. Muscle biopsy was attempted but was nondiagnostic and open surgical biopsy was considered. Due to
ongoing comorbid conditions, less invasive skin biopsy was
performed instead. Pathology at the site of violaceous rash on
forehead was consistent with dermatomyositis (Figures 2–4).
Given age and dysphagia at presentation, patient was
at high risk for underlying neoplastic process and a malignancy screen was performed. Serum paraneoplastic antibody
panel was positive only for striational antibody with titer
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Figure 4: Melanin incontinence into dermis (yellow arrow) (H&E
400x).
Figure 1: Peripheral blood smear with pancytopenia and teardrop
red blood cells (Wright 400x).

Figure 5: The bone is normocellular with megakaryocytic hyperplasia and moderate fibrosis (bone marrow, left posterior iliac crest,
clot section, and trephine core biopsies, 100x).

Figure 2: Epidermal atrophy with prominent basement membrane
(H&E 100x). Dermal edema with blue mucin and mild perivascular
mononuclear infiltrate (mainly lymphocytes).

Figure 3: Vacuolar change due to basal cell degeneration (H&E
200x). Civatte bodies at the papillary dermis. Prominent perivascular lymphocytes at left lower corner.

1 : 960. CSF paraneoplastic antibody was negative. CT with
contrast of the chest, abdomen, and pelvis was negative for
splenomegaly and masses.
Due to history of PV and declining blood counts, a
bone marrow biopsy was performed. Immunohistochemical staining with CD34, CD71, Factor VIII, and MPO
was performed. Pathologist review reported normocellular

Figure 6: Marrow reticulin fibers moderately increased with storage
iron present (bone marrow biopsy, left posterior iliac crest, and
reticulin stain, 400x).

marrow with megakaryocyte hyperplasia, mild decrease in
erythroid precursors, and moderate fibrosis (Figures 5-6).
Results were consistent with postpolycythemic myelofibrosis
(MF). Staging yielded IPSS 2 (INT-1) and DIPSS 3 (INT2), high intermediate to high risk MF. Given the temporal
relationship of symptom onset with conversion of PV to
MF, the patient was considered to have dermatomyositis
associated with secondary MF.
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Original treatment included prednisone 40 mg daily
and azathioprine 100 mg daily; however, symptoms progressed and pancytopenia worsened over 2 weeks. Azathioprine and prednisone were discontinued, and intravenous
immunoglobulin (IVIG) was administered. 1 day after treatment, the patient developed shortness of breath and was
found to have a pulmonary embolus with right peroneal
deep vein thrombosis. IVIG was subsequently discontinued
and the patient was treated with warfarin. Prednisone was
restarted at an increase of 60 mg daily and azathioprine was
restarted at 100 mg daily. The patient experienced gradual
resolution of weakness but required G-tube placement for
continued dysphagia.
At a six-month follow-up patient reported resolving
weakness with regain of ambulation and swallowing capacity.
At this time, prednisone is gradually being tapered. Postpolycythemic MF is currently managed with surveillance as
patient is not transfusion dependent and is not a transplant
candidate given poor performance status.

3. Discussion
Dermatomyositis (DM) is an autoimmune mediated inflammatory myopathy characterized by proximal muscle weakness and classic dermatologic findings including violaceous
pigmentation (heliotrope sign). Definitive diagnosis of DM
requires a skin or muscle biopsy in the setting of clinical
disease [1].
While the majority of DM is idiopathic in etiology,
15–30% of adult onset DM is associated with malignancy
[2, 3]. Risk factors of underlying malignancy in the setting
of adult onset DM include older age at disease onset,
dysphagia, evidence of capillary damage on muscle biopsy,
and cutaneous leukocytoclastic vasculitis [5–7]. While ovarian and lung cancers are most frequently identified with
DM, hematologic malignancies have also been associated,
most commonly B-cell lymphoma, T-cell lymphoma, and
myelodysplastic syndrome [8–11]. There have also been individual cases of primary myelofibrosis associated with DM
[4, 12, 13]. To our knowledge, this is the first case of secondary
myelofibrosis that has been associated with dermatomyositis.
Autoimmunity is a common theme of both DM and MF.
DM is a known autoimmune inflammatory myopathy and
MF is associated with increased autoantibody production
and circulating immune complexes [4, 12]. Additionally, the
association between autoimmune disorders and idiopathic
MF has been reported in 10–14% of cases [14–17]. This
case of postpolycythemic MF presents the possibility of an
immune paraneoplastic mechanism associating secondary
MF and DM. Regenerating muscle cells in myositis have been
observed to express antigens similar to cancer tissue [1, 18].
In the setting of hematologic malignancy, a paraneoplastic
immune response may inadvertently target muscle tissue
leading to DM.
The differential diagnosis of this case includes hydroxyurea induced DM-like eruption. Prior case reports have
shown development of DM while on hydroxyurea and resolution of DM after cessation of the medication [19, 20].
Given that this patient stopped hydroxyurea 2 months prior
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to the onset of DM, hydroxyurea induced DM is a less likely
diagnosis.
Immunosuppression with concurrent treatment of the
underlying malignancy is indicated in the setting of paraneoplastic DM. First-line immunosuppressive therapy often
includes prednisone. Prior cases of primary myelofibrosis
have shown response to azathioprine and prednisone regimens [12]. However, as seen in this case, neoplastic DM may
demonstrate poorer response to treatment than DM in the
absence of cancer [1]. High dose intravenous steroids have
been documented as a potential second-line therapy [21].
IVIG has also been shown to be beneficial in resistant cases
of DM [22, 23].
Prior case reports have documented resolution of DM
after treatment of underlying neoplasm [24, 25]. Unfortunately, given the poor clinical condition many patients
with paraneoplastic DM present with, surgical resection or
chemotherapy may not be tolerated.
An alternative therapeutic target may be the Janus Kinase
(JAK) 2 receptor with inhibitors such as ruxolitinib or
tofacitinib. JAK2 activating mutations including V617F have
been found in multiple myeloproliferative neoplasms such as
PV, essential thrombocytopenia, and MF [26]. JAK kinase
overactivity has also been noted in several autoimmune
disorders including rheumatoid arthritis, systemic lupus
erythematosus, and other autoantibody-driven diseases [27].
Given its activity in both autoimmune and myeloproliferative
processes, JAK2 inhibition would be a reasonable target in
paraneoplastic DM. Case reports documenting concurrent
resolution of dermatomyositis and post-PV MF after use of
ruxolitinib have been previously reported [28].
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